KR102470283B1 - 결정질 (3z,5s)-5-(하이드록시메틸)-1-[(2'-메틸-1,1'-바이페닐-4-일)카르보닐]피롤리딘-3-온 o-메틸옥심 - Google Patents

결정질 (3z,5s)-5-(하이드록시메틸)-1-[(2'-메틸-1,1'-바이페닐-4-일)카르보닐]피롤리딘-3-온 o-메틸옥심 Download PDF

Info

Publication number
KR102470283B1
KR102470283B1 KR1020177001267A KR20177001267A KR102470283B1 KR 102470283 B1 KR102470283 B1 KR 102470283B1 KR 1020177001267 A KR1020177001267 A KR 1020177001267A KR 20177001267 A KR20177001267 A KR 20177001267A KR 102470283 B1 KR102470283 B1 KR 102470283B1
Authority
KR
South Korea
Prior art keywords
methyl
biphenyl
carbonyl
hydroxymethyl
methyloxime
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177001267A
Other languages
English (en)
Korean (ko)
Other versions
KR20170023961A (ko
Inventor
앙드레 숄레
Original Assignee
옵스에파 에스에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 옵스에파 에스에이 filed Critical 옵스에파 에스에이
Publication of KR20170023961A publication Critical patent/KR20170023961A/ko
Application granted granted Critical
Publication of KR102470283B1 publication Critical patent/KR102470283B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
KR1020177001267A 2014-07-02 2015-06-10 결정질 (3z,5s)-5-(하이드록시메틸)-1-[(2'-메틸-1,1'-바이페닐-4-일)카르보닐]피롤리딘-3-온 o-메틸옥심 Active KR102470283B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462020076P 2014-07-02 2014-07-02
US62/020,076 2014-07-02
PCT/EP2015/062881 WO2016000920A1 (en) 2014-07-02 2015-06-10 Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity

Publications (2)

Publication Number Publication Date
KR20170023961A KR20170023961A (ko) 2017-03-06
KR102470283B1 true KR102470283B1 (ko) 2022-11-23

Family

ID=53434312

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177001267A Active KR102470283B1 (ko) 2014-07-02 2015-06-10 결정질 (3z,5s)-5-(하이드록시메틸)-1-[(2'-메틸-1,1'-바이페닐-4-일)카르보닐]피롤리딘-3-온 o-메틸옥심

Country Status (13)

Country Link
US (2) US9718772B2 (cg-RX-API-DMAC7.html)
EP (2) EP3164384B1 (cg-RX-API-DMAC7.html)
JP (4) JP2017519015A (cg-RX-API-DMAC7.html)
KR (1) KR102470283B1 (cg-RX-API-DMAC7.html)
CN (3) CN114105850A (cg-RX-API-DMAC7.html)
AU (1) AU2015283133B2 (cg-RX-API-DMAC7.html)
CA (1) CA2953722C (cg-RX-API-DMAC7.html)
EA (2) EA201891873A1 (cg-RX-API-DMAC7.html)
ES (1) ES2774789T3 (cg-RX-API-DMAC7.html)
IL (1) IL249652B (cg-RX-API-DMAC7.html)
MX (1) MX371068B (cg-RX-API-DMAC7.html)
UA (1) UA122210C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016000920A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
WO2016000920A1 (en) 2014-07-02 2016-01-07 ObsEva SA Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity
UA125118C2 (uk) 2016-01-04 2022-01-12 Обсева С.А. Альфа-аміноестери карбоксамідного похідного гідроксипропілтіазолідину та їх сольова форма, кристалічна поліморфна форма
AU2017300026B2 (en) * 2016-07-21 2023-07-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
WO2021043726A1 (en) 2019-09-03 2021-03-11 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
JP7083793B2 (ja) * 2019-09-10 2022-06-13 Ｊｆｅケミカル株式会社 パラターフェニルテトラカルボン酸およびパラターフェニルテトラカルボン酸二無水物の製造方法
CA3167121A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy
EP4313061A4 (en) * 2021-03-31 2025-03-05 The Board of Trustees of the Leland Stanford Junior University FORMULATIONS FOR PROLONGATION OF GESTATION AND FOR COMPLICATIONS OF MENSTRUATION OR GESTATION

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005249A1 (en) 2002-07-05 2004-01-15 Applied Research Systems Ars Holding N.V. Pyrrolidine derivatives as oxytocin antagonists

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU120988A (en) 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
YU183988A (en) 1988-09-30 1990-08-31 Lek Tovarna Farmacevtskih Process for preparing dispersion pills of dihydroergotoxine
US5089043A (en) 1989-11-09 1992-02-18 Shionogi & Co., Ltd. Heterocyclic oxy-phenoxyacetic acid derivatives and their use as herbicides
US5889001A (en) 1993-07-29 1999-03-30 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
JP3534903B2 (ja) 1995-06-09 2004-06-07 鐘淵化学工業株式会社 １−［３−クロロ−（２ｓ）−メチルプロピオニル］−ピロリジン−（２ｓ）−カルボン酸の製造方法
GB9603699D0 (en) 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
US6696484B2 (en) 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
CZ300558B6 (cs) 1999-12-09 2009-06-17 Reckitt Benckiser Healthcare (Uk) Limited Tabletová kompozice nesteroidního protizánetlivého léciva a zpusob její prípravy
US7018988B2 (en) 2000-03-27 2006-03-28 Applied Research Systems Ars Holding N.V. Pharmaceutically active pyrrolidine derivatives as Bax inhibitors
JP2003528854A (ja) 2000-03-27 2003-09-30 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 医薬として活性なピロリジン誘導体
US6821620B2 (en) 2000-07-13 2004-11-23 Nitto Denko Corporation Cleaning sheet, conveying member using the same, and substrate processing equipment cleaning method using them
ES2303854T3 (es) 2001-03-20 2008-09-01 Laboratoires Serono Sa Derivados de ester de pirrolidina con actividad moduladora de oxitocina.
KR200245627Y1 (ko) * 2001-05-15 2001-10-15 김병두 전기 가열부재가 부착된 냄비
HUP0400238A2 (hu) 2001-06-18 2004-07-28 Applied Research Systems Ars Holding N.V. Pirrolidin-oxadiazol- és tiadiazolszármazékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
JP2003192582A (ja) 2001-12-12 2003-07-09 Merck Patent Gmbh ナプロキセンナトリウムを含む速放性錠剤
DE602004024170D1 (de) 2003-02-27 2009-12-31 Merck Serono Sa Coinsins Pyrrolidin-derivate als oxytocin antagonisten
BRPI0508059A (pt) 2004-02-26 2007-07-17 Applied Research Systems método para preparação de pirrolidina oximas
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
EP1879572B1 (en) 2005-05-10 2011-05-04 Ferring B.V. Use of antagonists of oxytocin and/or vasopressin in assisted reproduction
JP2008189732A (ja) 2007-02-01 2008-08-21 Fujifilm Corp セルロースアシレート組成物、セルロースアシレートフィルム、光学補償シート、偏光板および液晶表示装置
CA2703501C (en) 2007-10-01 2017-06-13 Laboratorios Lesvi, S.L. Orodispersible tablets
US9201077B2 (en) 2009-07-27 2015-12-01 Colorado State University Research Foundation Direct enzyme immunoassay for measurement of serum progesterone levels
EP2922475A1 (en) 2012-11-26 2015-09-30 Ferring BV Method and system for diagnosing uterine contraction levels using image analysis
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) * 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
WO2016000920A1 (en) 2014-07-02 2016-01-07 ObsEva SA Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity
PL3037101T3 (pl) 2014-12-22 2019-06-28 Ferring B.V. Terapia antagonistą receptora oksytocyny w fazie lutealnej w celu implantacji i uzyskania ciąży u kobiet poddawanych technikom wspomaganego rozrodu

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005249A1 (en) 2002-07-05 2004-01-15 Applied Research Systems Ars Holding N.V. Pyrrolidine derivatives as oxytocin antagonists

Also Published As

Publication number Publication date
US9718772B2 (en) 2017-08-01
US20160002160A1 (en) 2016-01-07
EA201891873A1 (ru) 2019-04-30
UA122210C2 (uk) 2020-10-12
EA031353B1 (ru) 2018-12-28
IL249652B (en) 2021-09-30
ES2774789T3 (es) 2020-07-22
EP3753921A1 (en) 2020-12-23
EA201790080A1 (ru) 2017-06-30
AU2015283133A1 (en) 2017-02-16
US20170320822A1 (en) 2017-11-09
JP2021038236A (ja) 2021-03-11
CN114105851A (zh) 2022-03-01
IL249652A0 (en) 2017-02-28
CA2953722C (en) 2022-09-13
CN114105850A (zh) 2022-03-01
JP2017519015A (ja) 2017-07-13
EP3164384A1 (en) 2017-05-10
MX2016016751A (es) 2017-08-08
JP2025013885A (ja) 2025-01-28
MX371068B (es) 2020-01-15
US10752583B2 (en) 2020-08-25
EP3164384B1 (en) 2019-12-04
WO2016000920A1 (en) 2016-01-07
CA2953722A1 (en) 2016-01-07
KR20170023961A (ko) 2017-03-06
AU2015283133B2 (en) 2019-05-16
CN106795110A (zh) 2017-05-31
JP2023018037A (ja) 2023-02-07

Similar Documents

Publication Publication Date Title
KR102470283B1 (ko) 결정질 (3z,5s)-5-(하이드록시메틸)-1-[(2'-메틸-1,1'-바이페닐-4-일)카르보닐]피롤리딘-3-온 o-메틸옥심
AU2014364962B2 (en) Oral formulations of pyrrolidine derivatives
AU2018201730B2 (en) PYRROLIDINE DERIVATIVES AS OXYTOCIN / VASOPRESSIN V1a RECEPTORS ANTAGONISTS
HK40039130A (en) Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2’-methyl-1,1’-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity
HK1231866A1 (en) Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity
HK1231866B (en) Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime useful in methods of treating conditions related to the ot-r activity
BR112016030894B1 (pt) Composto cristalino, composição farmacêutica e método para preparar um composto cristalino
EA049934B1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛИДИНА В КАЧЕСТВЕ АНТАГОНИСТОВ РЕЦЕПТОРОВ ОКСИТОЦИНА/ВАЗОПРЕССИНА V1a

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4